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Herceptin (Trastuzumab), a monoclonal antibody targeting
HER2 has been demonstrated to improve survival of
HER2 overexpressing metastatic breast cancer. However,
half of patients who initially respond to Herceptin
develop resistance within one year of treatment initiation,
and in the adjuvant setting 15% of patients still relapse
after one year of treatment despite Herceptin-based ther-
apy. Alteration of Antibodies Dependant Cellular Cyto-
toxicity (ADCC) is one of the rational mechanisms for
resistance to therapeutic Mab. The goal of this project is
to overcome this resistance by adoptive transfer using
genetically engineered optimized NK cells. We thus com-
pare efficacy of two different approaches : (i) NK cells
armed with a high affinity Fc domain (FcgRIIIa, CD16)
linked to its transduction chain FCεRIg (CD16/g) to allow
recognition and interaction with Mab, inducing ADCC
and (ii) NK cells expressing Herceptin sequence fused to
the transduction chain FCεRIg(CD16/g) to directly kill
the HER2 positively cells. Results obtained in vitro
demonstrated higher direct killing efficacy of NK expres-
sing Herceptin/g against HER2 amplified breast carci-
noma cells. However, abnormal reactivity against cells
with undetectable HER2 expression by FACS analysis
was observed. This last point might represent an impor-
tant limitation point for clinical use. On the other hand,
“two step killing by ADCC” with NK-CD16/g demon-
strated a very specific cytotoxicity against HER2 positive
cells through ADCC only in the presence of antibody.
We demonstrated that efficacy of specific lysis is linked
(i) to effector dose, (ii) levels of CD16/g expression on
effectors cells, (iii) HER2 expression but not level on
target cells In Herceptin resistant HER2+ xenograft
immunodeficient NSG mice model, complete regression
was obtained only with NK- CD16/g in the presence of
Herceptin. Our last results will be discussed. Restoration
or improvement of effectors cells might be considerate as
an issue in therapeutic humanized Mab resistance treat-
ment. Successful immune-based therapies will likely ulti-
mately integrate strategies that combine immunotherapy
approaches and immune-modulating drugs, in order to
maximize their antitumor activity.
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